Phase I Clinical Study for KY2 Liquid Capsules targeting DHX33 has been initiated in China
2026-08-29
Investigation New Drug application approved by FDA for KY386 Injection for treating AML/T-ALL
KeYe Life won the 'Medical Technology Innovation Award' at the 6th International Science and Technology Innovation Festival
2026-01-27
Milestones of innovation in the year of 2025
2026-01-04
Keye Life Showcases RNA Helicase Platform at BIONNOVA South China Innovation Forum 2025
2025-12-11
Keye Life Secures Second Prize in SZIC with World's First DHX33 Inhibitor Project
2025-11-04
